


# Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP):

## GENERAL PROTOCOL





# **Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP):**

## **GENERAL PROTOCOL**



**World Health  
Organization**

Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP): general protocol

ISBN 978-92-4-002134-1 (electronic version)

ISBN 978-92-4-002135-8 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP): general protocol. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned.

Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout by 400 Communications.

## CONTENTS

<b>Acknowledgements</b>	<b>iv</b>
<b>Abbreviations and acronyms</b>	<b>v</b>
<b>1. Introduction</b>	<b>1</b>
1.1 Objectives of EGASP	2
<b>2. Methods</b>	<b>3</b>
2.1. Surveillance setting	4
2.2. Inclusion criteria	4
2.2.1. Informed consent	5
2.3. Collection, handling and transporting specimens	5
2.4. Isolating and identifying <i>Neisseria gonorrhoeae</i>	5
2.5. Preserving isolates	6
2.6. Antimicrobial susceptibility testing	6
2.7. External quality assessment	7
2.8. Treating and managing patients	8
2.9. EGASP data	8
2.9.1. Collecting, storing and reporting EGASP data	8
2.9.2. Data analysis	9
2.10 Monthly and annual process measure reporting	9
<b>3. Data reporting to WHO, CDC/DSTD/P/NCHHSTP and WHO collaborating centre</b>	<b>11</b>
3.1 EGASP module in GLASS	12
<b>4. Roles and responsibilities of institutions and partners implementing EGASP</b>	<b>13</b>
4.1. Health Ministry (or other entity appointed by the Ministry)	14
4.2. Other national partners in the country	14
4.3. EGASP sentinel clinic(s)	14
4.4. EGASP reference laboratories	15
4.5. WHO	15
4.6. CDC/DSTD/P/NCHHSTP and WHO collaborating centre	16
<b>5. General issues</b>	<b>17</b>
5.1. Timelines for EGASP implementation and communication	17
5.2. Disseminating and using EGASP data and specimens and isolates	18
5.3. Human subjects	19
5.4. Authorship of EGASP data	19
<b>References</b>	<b>21</b>
<b>Annex 1. Participating EGASP institutions and partners</b>	<b>22</b>
<b>Annex 2. Methods for antimicrobial susceptibility testing</b>	<b>23</b>
<b>Annex 3. EGASP data elements</b>	<b>26</b>
<b>Annex 4. Monthly and annual process measure reporting</b>	<b>34</b>
<b>Annex 5. Summary of EGASP timelines for project participants</b>	<b>35</b>
<b>Annex 6. Use of EGASP data and specimens and isolates, including the EGASP concept proposal form</b>	<b>36</b>
<b>EGASP concept proposal form for data and isolates, including requests for compiling an abstract or manuscript</b>	<b>37</b>

## ACKNOWLEDGEMENTS

WHO thanks the **Member States, WHO Collaborating Centre for Gonorrhoea and other STIs, Örebro University, Sweden, WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, Prince of Wales University, Randwick, Australia** and our technical partners who supported the development and pilot testing of the Enhanced Gonorrhoea Surveillance Programme (EGASP) protocol. The work of the dedicated health-care providers and partners at the local and national levels informed the development of this protocol.

WHO is grateful for the technical input of the following people: **Hortense Faye-Kette** (Institut Pasteur de Côte d'Ivoire), **Eric Garges** (STI Research Area, Infection Disease Clinical Research Program, Bethesda, MD, USA), **Natnaree Girdthep, Rossaphorn Kittiyaowamarn and Pachara Sirivongrangson** (Department of Disease Control, Ministry of Public Health, Thailand), **Ranmini Kularatne** (National Institute of Communicable Diseases, South Africa), **Monica Lahra** (WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, Prince of Wales University, Australia), **Noel Palaypayon** (Epidemiology Bureau, Department of Health, Philippines), **Genesis Samonte** (public health specialist), **Joseph Carlo Sangco** (STD AIDS Cooperative Central Laboratory, San Lazaro Hospital, Philippines), **Sonia Sia** (Research Institute of Tropical Medicine, Philippines), **Gianfranco Spiteri** (European Centre for Disease Prevention and Control), **Katy Town** (Public Health England), **Magnus Unemo** (WHO Collaborating Centre for Gonorrhoea and other STIs, Örebro University, Sweden), **Nerissa Dominguez** (WHO Country Office in the Philippines), **Naoko Ishikawa and Anne Brink** (WHO Regional Office for the Western

Pacific) and **Mukta Sharma and Bharat Rewari** (WHO Regional Office for South-East Asia). Additional input was provided by **Barbara Tornimbene** (Global Antimicrobial Resistance and Use Surveillance System (GLASS), WHO).

**Teodora Wi** (WHO Global HIV, Hepatitis and Sexually Transmitted Infections Programme) and **Hillard Weinstock and Ellen Kersh** (Division of STD Prevention, United States Centers for Disease Control and Prevention) led the development of this protocol. **Cau Dinh Pham and Emily Weston** (Division of STD Prevention, United States Centers for Disease Control and Prevention) and **Martina Escher** (WHO Global HIV, Hepatitis and Sexually Transmitted Infections Programme) compiled the protocol.

WHO is grateful for the technical review and comments provided by **Jo-Anne Dillon** (University of Saskatchewan, Canada) and **Olusegun O. Soge** (University of Washington, USA).

WHO thanks the **United States Centers for Disease Control and Prevention** for their financial support and for the technical contributions of other colleagues dedicated to strengthening the gonorrhoea antimicrobial resistance surveillance at the country, regional and global levels.

WHO thanks the **Ministry of Public Health of Thailand** and the **Department of Health of the Philippines** for the commitment to pilot EGASP in their countries and to the EGASP teams from both countries for the day-to-day work in implementing EGASP. WHO recognizes the ongoing efforts of Member States as they continue to work to improve sexually transmitted infection surveillance and service delivery at the national level.

## ABBREVIATIONS AND ACRONYMS

AMR	Antimicrobial resistance
CDC/DSTD/PNCHHSTP	United States Centers for Disease Control and Prevention, Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STDs and TB Prevention
GASP	Gonococcal Antimicrobial Surveillance Programme
EGASP	Enhanced Gonococcal Antimicrobial Surveillance Programme
EUCAST	European Committee on Antimicrobial Susceptibility Testing
GAP-AMR	Global Action Plan on Antimicrobial Resistance
GLASS	Global Antimicrobial Resistance and Use Surveillance System (GLASS)
ISO	International Organization for Standardization
MIC	minimum inhibitory concentration

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23892](https://www.yunbaogao.cn/report/index/report?reportId=5_23892)

